Related Experiment Video

Updated: May 26, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

MATN1-AS1 Promotes Tumour Metastasis and Sunitinib Resistance via E2F2 in Clear Cell Renal Cell Carcinoma

Haibing Xiao1,2, Mintian Fei1,2, Qili Xu1,2

  • 1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Journal of Cellular and Molecular Medicine
|February 25, 2025
PubMed

Insights

The long non-coding RNA MATN1-AS1 promotes clear cell renal cell carcinoma (ccRCC) metastasis and sunitinib resistance by upregulating E2F2. Targeting MATN1-AS1 may offer a new strategy to overcome drug resistance in ccRCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) are increasingly implicated in various cancers.
  • The specific role of MATN1-AS1 in clear cell renal cell carcinoma (ccRCC) remains largely unexplored.
  • Understanding lncRNA functions is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the molecular mechanisms of MATN1-AS1 in ccRCC progression.
  • To determine the association between MATN1-AS1 and ccRCC metastasis and sunitinib resistance.
  • To explore MATN1-AS1 as a potential therapeutic target for ccRCC.

Main Methods:

  • Quantitative real-time PCR to assess MATN1-AS1 expression levels.
  • Cell proliferation, migration, and invasion assays to evaluate cellular functions.
  • In vivo tumor xenograft models to study tumor growth and metastasis.
  • Western blotting and luciferase reporter assays to elucidate molecular pathways.

Main Results:

  • MATN1-AS1 is upregulated in ccRCC tissues and associated with poor clinical outcomes.
  • Downregulation of MATN1-AS1 inhibits ccRCC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).
  • MATN1-AS1 promotes ccRCC tumor growth and metastasis in vivo.
  • MATN1-AS1 acts as a molecular sponge for miR-214-5p, leading to E2F2 upregulation and EMT promotion.
  • MATN1-AS1 enhances sunitinib resistance in ccRCC cells via E2F2.

Conclusions:

  • MATN1-AS1 exhibits significant protumorigenic functions in ccRCC.
  • MATN1-AS1 promotes ccRCC metastasis and resistance to sunitinib treatment.
  • MATN1-AS1 represents a potential therapeutic target for reversing sunitinib resistance in ccRCC.
Keywords:
E2F2EMTMATN1‐AS1ccRCClncRNAsunitinib resistance

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
10.1K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K